Contact Us
Drug Search Results
More Filters [+]

AT-7519

Alternative Names: at-7519, at7519
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: NCIC Clinical Trials Group
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AT-7519

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2015-01098

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2020-08-15

I177

P1

Completed

Lymphoma

2012-03-13

Recent News Events

Date

Type

Title

04/01/2024

PubMed

 An allosteric mechanism for potent inhibition of SARS-CoV-2 main proteinase.

01/19/2024

PubMed

 Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors.

11/14/2023

PubMed

 A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions